Literature DB >> 32306375

Clinical and functional consequences of anti-properdin autoantibodies in patients with lupus nephritis.

M Radanova1, G Mihaylova1, D Ivanova1, M Daugan2, V Lazarov3, L Roumenina2, V Vasilev3.   

Abstract

Properdin is the only positive regulator of the complement system. In this study, we characterize the prevalence, functional consequences and disease associations of autoantibodies against properdin in a cohort of patients with autoimmune disease systemic lupus erythematosus (SLE) suffering from lupus nephritis (LN). We detected autoantibodies against properdin in plasma of 22·5% of the LN patients (16 of 71) by enzyme-linked immunosorbent assay (ELISA). The binding of these autoantibodies to properdin was dose-dependent and was validated by surface plasmon resonance. Higher levels of anti-properdin were related to high levels of anti-dsDNA and anti-nuclear antibodies and low concentrations of C3 and C4 in patients, and also with histological signs of LN activity and chronicity. The high negative predictive value (NPV) of anti-properdin and anti-dsDNA combination suggested that patients who are negative for both anti-properdin and anti-dsDNA will not have severe nephritis. Immunoglobulin G from anti-properdin-positive patients' plasma increased the C3b deposition on late apoptotic cells by flow cytometry. Nevertheless, these IgGs did not modify substantially the binding of properdin to C3b, the C3 convertase C3bBb and the pro-convertase C3bB, evaluated by surface plasmon resonance. In conclusion, anti-properdin autoantibodies exist in LN patients. They have weak but relevant functional consequences, which could have pathological significance.
© 2020 British Society for Immunology.

Entities:  

Keywords:  complement; lupus nephritis; properdin

Mesh:

Substances:

Year:  2020        PMID: 32306375      PMCID: PMC7366743          DOI: 10.1111/cei.13443

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis.

Authors:  Iglika K Djoumerska-Alexieva; Jordan D Dimitrov; Elisaveta N Voynova; Sebastien Lacroix-Desmazes; Srinivas V Kaveri; Tchavdar L Vassilev
Journal:  FEBS J       Date:  2010-06-08       Impact factor: 5.542

2.  Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers.

Authors:  E Akhter; R W Burlingame; A L Seaman; L Magder; M Petri
Journal:  Lupus       Date:  2011-08-03       Impact factor: 2.911

3.  Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease.

Authors:  Azadeh Zaferani; Romain R Vivès; Pieter van der Pol; Jelleke J Hakvoort; Gerjan J Navis; Harry van Goor; Mohamed R Daha; Hugues Lortat-Jacob; Marc A Seelen; Jacob van den Born
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

4.  Metabolism of properdin in normal subjects and patients with renal disease.

Authors:  J B Ziegler; F S Rosen; C A Alper; W Grupe; I H Lepow
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

Review 5.  Properdin and complement activation: a fresh perspective.

Authors:  Dennis E Hourcade
Journal:  Curr Drug Targets       Date:  2008-02       Impact factor: 3.465

6.  Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.

Authors:  N Marto; M L Bertolaccini; E Calabuig; G R V Hughes; M A Khamashta
Journal:  Ann Rheum Dis       Date:  2004-07-29       Impact factor: 19.103

Review 7.  Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.

Authors:  Mihály Józsi; Stefanie Reuter; Pilar Nozal; Margarita López-Trascasa; Pilar Sánchez-Corral; Zoltán Prohászka; Barbara Uzonyi
Journal:  Immunol Lett       Date:  2014-02-01       Impact factor: 3.685

8.  Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b.

Authors:  Ramon M van den Bos; Nicholas M Pearce; Joke Granneman; T Harma C Brondijk; Piet Gros
Journal:  Front Immunol       Date:  2019-09-04       Impact factor: 7.561

9.  Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus.

Authors:  Olivier C Meyer; Pascale Nicaise-Roland; Nolwenn Cadoudal; Sabine Grootenboer-Mignot; Elisabeth Palazzo; Gilles Hayem; Philippe Dieudé; Sylvie Chollet-Martin
Journal:  Arthritis Res Ther       Date:  2009-06-10       Impact factor: 5.156

10.  Antibodies against C1q Are a Valuable Serological Marker for Identification of Systemic Lupus Erythematosus Patients with Active Lupus Nephritis.

Authors:  Shuhong Chi; Yunxia Yu; Juan Shi; Yurong Zhang; Jijuan Yang; Lijuan Yang; Xiaoming Liu
Journal:  Dis Markers       Date:  2015-10-13       Impact factor: 3.434

View more
  1 in total

Review 1.  Ex Vivo Test for Measuring Complement Attack on Endothelial Cells: From Research to Bedside.

Authors:  Marie-Sophie Meuleman; Anna Duval; Véronique Fremeaux-Bacchi; Lubka T Roumenina; Sophie Chauvet
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.